Navigation Links
Response Biomedical Corporation Receives Conditional Listing Approval from the Toronto Stock Exchange
Date:11/6/2007

VANCOUVER, Nov. 6 /PRNewswire-FirstCall/ - Response Biomedical Corporation (TSX-V: RBM, OTCBB: RPBIF) is pleased to announce that the Toronto Stock Exchange (TSX) has conditionally approved the Company's application for listing its common shares on the TSX. Listing on the TSX will be subject to the Company filing satisfactory final documentation with the TSX. The Company will issue a news release when final listing approval has been granted by the TSX.

About Response Biomedical

Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its portable RAMP(R) Platform for clinical and environmental applications. RAMP(R) represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point-of-care testing and laboratory use. The RAMP(R) system consists of a portable fluorescent reader and single-use disposable test cartridges, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. RAMP(R) clinical tests are commercially available for the early detection of heart attack and congestive heart failure.

In late 2006, the Company formed a strategic alliance with 3M Company to commercialize rapid infectious disease tests. In the non-clinical market, RAMP Tests are currently provided for the environmental detection of West Nile Virus, and Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Several other product applications are under development. The Company has achieved CE Marking and its Quality Management System is registered to ISO 13485: 2003 and ISO 9001: 2000.

Response Biomedical is a publicly traded company, listed on the TSX Venture Exchange under the trading symbol "RBM" and quoted on the OTC Bulletin Board under the symbol "RPBIF". For further information, please visit the Company's website at

SOURCE Response Biomedical Corp.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Tumors use enzyme to recruit regulatory T-cells and suppress immune response
2. Study identifies key player in the bodys immune response to chronic stress
3. Retired NYPD Lieutenants William E. Keegan, Jr., Owen McCaffery and John Moran and Tom Thees, a former COO in the financial industry, announce today the formation of H.E.A.R.T (Healing Emergency Aid Response Team) 911.
4. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
5. Merck & Co., Inc. Response to Todays New York Medicaid Suit
6. Maternal depression and controlling behavior associated with increased stress response in infants
7. Family history of alcoholism affects response to drug used to treat heavy drinking
8. Molecular fingerprint of breast-cancer drug resistance can predict response to treatment
9. Breast cancer susceptibility gene predicts outcome and response to treatment in lung cancer
10. PET scans can accurately detect a breast tumors response to chemotherapy
11. DNA damage response confers a barrier for viral tumorigenesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...orporation Executive, Robert J. Reilly, Joins Aeth...on Inc.,( http://www.aethon.com ), the leading dev...n logistics, today announced that Robert J. Reilly...- Chief Financial Officer., Reilly, who was most ...esson Corporation,s Specialty Pharmacy Division, b...
(Date:7/25/2008)...25 /PRNewswire/ -- The Elekta Family of Companies ...t solutions at the 2008,American Association of Ph...trating how the joint forces of Elekta, IMPAC and ...planning and delivery solutions that,streamline th...for,patients, as well as enhance clinician efficie...
(Date:7/25/2008)...f., July 25 /PRNewswire/ -- AutoGenomics, Inc. tod...ement on Form S-1 with the,Securities and Exchange...c,offering of shares of its common stock. The numb... which are expected to be offered by,AutoGenomics,...not yet been,determined., J.P. Morgan Securities ...
(Date:7/25/2008)...ughest for those trying to drop pounds, study find...- Anyone who has avoided Monday morning weigh-ins ...ieter,s friend. , Now, researchers have some sc...s being their undoing: Most people do eat more on ...ht. , "Weekend indulgences can wreak havoc on w...
Breaking Medicine News(10 mins):Health News:Aethon, Inc. Names New Chief Financial Officer 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2Health News:Weekends Tough on the Diet 2Health News:Weekends Tough on the Diet 3
...er Medical Centre say that the antipsychotic drug,...//Clopazine is the most effective anti-psychotic d...ny people. But there are long-term health implicat...ts who need the most effective medication are betw...
...s that simply reducing the fat. It can actually pr...cGill University// . The researchers studied 1,0...The study followed these people from 1986 to 2002....rgery during this period. The results were compare...
...eaves you with a hit in the head with the ball. Wh... little dizzy and queasy// you often just continue...and nausea are two signs of concussion—one of the ...ed Shannon, head athletic trainer and instructor a...
... all the popular opinion by saying that beer is a ...bringing cheers// to all the beer lovers. Charles... at the University of California at Davis and an A...food scientists assembled here Tuesday that beer c...
Other Medicine News:Health News:Beer is More Healthier Than Wine 2
(Date:7/22/2008)...ility and Efficacy of Treating Patients with ...NCISCO, and YONGIN-SI, South Korea, July 22 /PRNew...tawa, Ontario), and its South,Korean partner Green...from,a Phase I clinical trial of its first-in-clas...t was well-tolerated and resulted in clear,anti-ca...
(Date:7/22/2008)...tress the Importance to Patients of Passing a ... RICHMOND, Va., July 22 /-...ow-on biologics and biopharmaceuticals, today,anno...ill present at a,Congressional briefing on Friday,...or establishing an approval pathway for follow-on,...
(Date:7/22/2008)... by Columbia University Medical Center Based on ...hnology, The Test Differentiates Squamous From N...lassifying Squamous-Cell Carcinoma of the Lung Wit... of 90 Percent,This is the First CLIA Approved Tes...as Biomarkers for Accurate Diagnosis of Lung Cance...
(Date:7/22/2008)...idual,s Genetic Risk Based on Clinical Data, Pr...al Materials, WALTHAM, Mass., July 22 /PRNewswire...ILI ), today announced the launch of an enhanced t...company,s Heart Health Genetic Test.,The test is c...Heart Health,Genetic Test by Quixtar/Amway. The ne...
Breaking Medicine Technology:Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 2Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 4Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 2Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 2First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 5Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 2Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 3Researchers successfully simulate photosynthesis and design a better leaf 1169 1Researchers successfully simulate photosynthesis and design a better leaf 1169 2Researchers successfully simulate photosynthesis and design a better leaf 1169 3Abnormal immune cells may cause unprovoked anaphylaxis 5990 1Abnormal immune cells may cause unprovoked anaphylaxis 5990 2Abnormal immune cells may cause unprovoked anaphylaxis 5990 3Research highlights important indicators of early stage ovarian cancer 5988 1New technology illuminates protein interactions in living cells 1167 1New technology illuminates protein interactions in living cells 1167 2
...ion Therapeutics,announced today that data on two ...prednate) and ST-602 (fenretinide), will be,presen...for,Research in Vision and Ophthalmology (ARVO) in...tions, the company will be hosting a,reception for...ntly being evaluated in two phase,III clinical tri...
...erlying Cause of,Genetic Disorders and Restores Pr...2007 /PRNewswire/ -- New,preclinical data publishe...ure show that PTC124, an investigational new drug,...ious in a,preclinical model of Duchenne muscular d... 13 percent of the cases of DMD are due,to nonsens...
Other Medicine Technology:Sirion Therapeutics Announces Clinical Data to be Presented at the,2007 Association for Research in Vision and Ophthalmology (ARVO),Annual Meeting 2Sirion Therapeutics Announces Clinical Data to be Presented at the,2007 Association for Research in Vision and Ophthalmology (ARVO),Annual Meeting 3Sirion Therapeutics Announces Clinical Data to be Presented at the,2007 Association for Research in Vision and Ophthalmology (ARVO),Annual Meeting 4Targeting Specific Mutations Reveals Promising New Approach to,Treating Genetic Disorders; Preclinical Data Published in Nature 2Targeting Specific Mutations Reveals Promising New Approach to,Treating Genetic Disorders; Preclinical Data Published in Nature 3Targeting Specific Mutations Reveals Promising New Approach to,Treating Genetic Disorders; Preclinical Data Published in Nature 4
Blunt Tapered Tip in stainless steel.
...ipurpose gamma camera is designed for SPECT and PE...mbines the high-energy and PET imaging capability ...ECT and planar imaging, all in one unit.,The ...nd general nuclear medicine applications well beyo...
In Stainless steel. Available in 1.5, 2.0,3.0 & 3.5 MM
AXIOM Artis FA is a universal floor-mounted angiographic C-arm system whose flexible system architecture is ideal for vascular and non-vascular diagnostics and interventions. It provides complete erg
Medicine Products: